Jennifer Johnson

TitleAsst Professor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address925 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shaver AL, Nikita N, Sharma S, Lefler DS, Basu-Mallick A, Johnson JM, Butryn ML, Lu-Yao G. Understanding the role of sex on outcomes for the cancer patient undergoing treatment with immune checkpoint inhibitors: a scoping review protocol. BMJ Open. 2022 Jul 21; 12(7):e059782. PMID: 35863824.
      Citations:    
    2. Vathiotis IA, Johnson JM, Luginbuhl A, Cognetti D, Curry J, Argiris A. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches. Cancer Treat Rev. 2022 Jul 16; 109:102437. PMID: 35868194.
      Citations:    
    3. Domingo-Vidal M, Whitaker-Menezes D, Mollaee M, Lin Z, Tuluc M, Philp N, Johnson JM, Zhan T, Curry J, Martinez-Outschoorn U. Monocarboxylate Transporter 4 in Cancer-Associated Fibroblasts Is a Driver of Aggressiveness in Aerodigestive Tract Cancers. Front Oncol. 2022; 12:906494. PMID: 35814364.
      Citations:    
    4. Quinn ZL, Barta JA, Johnson JM. Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care. Am J Med Sci. 2022 Apr 22. PMID: 35469765.
      Citations:    
    5. Nikita N, Banks J, Keith SW, Song A, Johnson JM, Wilson M, Sharma S, Lu-Yao G. Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study. Cancers (Basel). 2022 Mar 02; 14(5). PMID: 35267602.
      Citations:    
    6. Luginbuhl AJ, Johnson JM, Harshyne LA, Linnenbach AJ, Shukla SK, Alnemri A, Kumar G, Cognetti DM, Curry JM, Kotlov N, Antysheva Z, Degryse S, Mannion K, Gibson MK, Netterville J, Brown B, Axelrod R, Zinner R, Tuluc M, Gargano S, Leiby BE, Shimada A, Mahoney MG, Martinez-Outschoorn U, Rodeck U, Kim YJ, South AP, Argiris A. Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Mar 01; 28(5):915-927. PMID: 34911681.
      Citations:    
    7. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291. PMID: 35033226.
      Citations:    
    8. Shaver AL, Sharma S, Nikita N, Lefler DS, Basu-Mallick A, Johnson JM, Butryn M, Lu-Yao G. The Effects of Physical Activity on Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors: A Scoping Review. Cancers (Basel). 2021 Dec 18; 13(24). PMID: 34944984.
      Citations:    
    9. Jang SR, Nikita N, Banks J, Keith SW, Johnson JM, Wilson M, Lu-Yao G. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma. JAMA Netw Open. 2021 12 01; 4(12):e2136823. PMID: 34854905.
      Citations:    
    10. Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, Fidler MJ, Stenson K, Vasan NR, Razaq MA, Campana J, Ha P, Mann G, Ishida K, Garcia-Guzman M, Biel M, Gillenwater AM. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 Oct 09. PMID: 34626024.
      Citations:    
    11. Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, Chintakuntlawar AV, Pawlicki J, Sylvester AJ, McMullan T, Samuels R, Kim JJ, Weiner D, Boyer JD, Morrow MP, Humeau L, Skolnik JM. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. J Immunother Cancer. 2021 07; 9(7). PMID: 34230114.
      Citations:    
    12. Vathiotis IA, Johnson JM, Argiris A. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. Cancer Treat Rev. 2021 Mar 24; 97:102192. PMID: 33819755.
      Citations:    
    13. Merlino DJ, Johnson JM, Tuluc M, Gargano S, Stapp R, Harshyne L, Leiby BE, Flanders A, Zinner R, Axelrod R, Curry J, Cognetti DM, Mannion K, Kim YJ, Rodeck U, Argiris A, Luginbuhl AJ. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. Front Oncol. 2020; 10:566315. PMID: 33344227.
      Citations:    
    14. South AP, den Breems NY, Richa T, Nwagu U, Zhan T, Poojan S, Martinez-Outschoorn U, Johnson JM, Luginbuhl AJ, Curry JM. Mutation signature analysis identifies increased mutation caused by tobacco smoke associated DNA adducts in larynx squamous cell carcinoma compared with oral cavity and oropharynx. Sci Rep. 2019 Dec 17; 9(1):19256. PMID: 31848367.
      Citations:    
    15. Lin J, Song AJ, Hoffman-Censits J, Leiby BE, Tuluc M, Shaw C, Harshyne L, Kean R, Bar-Ad V, Den RB, Hurwitz MD, Louie J, Philipose S, Deshmukh SP, Johnson JM, Dicker AP, Hooper DC, Kelly WK, Lu B. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. Am J Clin Oncol. 2019 Nov 05. PMID: 31693508.
      Citations:    
    16. Bar-Ad V, Hubley E, Luginbuhl A, Cognetti D, Curry J, Harrison AS, Johnson JM, Keller J, Peng C, To D, Doyle L. Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma. J Contemp Brachytherapy. 2019 Jun; 11(3):227-234. PMID: 31435429.
      Citations:    
    17. Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM. Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019; 9:122. PMID: 30895168.
      Citations:    
    18. Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, Johnson JM. Metformin as a Therapeutic Target in Endometrial Cancers. Front Oncol. 2018; 8:341. PMID: 30211120.
      Citations:    
    19. Johnson JM, Cotzia P, Fratamico R, Mikkilineni L, Chen J, Colombo D, Mollaee M, Whitaker-Menezes D, Domingo-Vidal M, Lin Z, Zhan T, Tuluc M, Palazzo J, Birbe RC, Martinez-Outschoorn UE. MCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer. Front Cell Dev Biol. 2017; 5:27. PMID: 28421181.
      Citations:    
    20. Johnson JM, Chen J, Ali SM, Dardi IK, Tuluc M, Cognetti D, Campling B, Sama AR. Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome. J Gastrointest Cancer. 2016 Oct 6. PMID: 27714650.
      Citations:    
    21. Gill KS, Tassone P, Hamilton J, Hjelm N, Luginbuhl A, Cognetti D, Tuluc M, Martinez-Outschoorn U, Johnson JM, Curry JM. Thyroid Cancer Metabolism: A Review. J Thyroid Disord Ther. 2016 Feb; 5(1). PMID: 27213120.
      Citations:    
    22. Johnson JM, Lai SY, Cotzia P, Cognetti D, Luginbuhl A, Pribitkin EA, Zhan T, Mollaee M, Domingo-Vidal M, Chen Y, Campling B, Bar-Ad V, Birbe R, Tuluc M, Martinez Outschoorn U, Curry J. Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. Semin Oncol. 2015 Dec; 42(6):915-22. PMID: 26615136.
      Citations:    
    23. Kistler CA, Johnson JM, Winter JM, Baliff JP, Siddiqui AA, Sama AR. A case of periampullary adenocarcinoma in neurofibromatosis type 1. J Gastrointest Oncol. 2014 Dec; 5(6):E96-9. PMID: 25436139.
      Citations:    
    24. Latimer JJ, Johnson JM, Miles TD, Dimsdale JM, Edwards RP, Kelley JL, Grant SG. Cell-type-specific level of DNA nucleotide excision repair in primary human mammary and ovarian epithelial cell cultures. Cell Tissue Res. 2008 Sep; 333(3):461-7. PMID: 18575893; PMCID: PMC4301738.
      Citations:    
    Johnson's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (42)
    Explore
    _
    Co-Authors (42)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _